To investigate the importance of BCR-ABL degradation in CML growth inhibition by DAS-IAP, we developed a structurally related inactive degrader as a control compound, which is composed of dasatinib and an N-methylated LCL161 derivative (DAS-meIAP) that cannot recruit IAPs. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.